Inozyme Pharma, Inc. (INZY)
Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)
4.000
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025

Inozyme Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
26017826342161482
Market Cap Growth
--32.37%520.31%-73.72%-66.55%-
Enterprise Value
22293105-9240323
Last Close Price
4.002.774.261.056.8220.64
PB Ratio
8.173.081.870.361.483.05
P/TBV Ratio
8.173.081.870.361.483.05
Debt / Equity Ratio
1.480.810.330.060.03-
Quick Ratio
1.983.3512.878.709.6214.83
Current Ratio
2.193.5613.368.939.9115.14
Return on Equity (ROE)
-141.69%-102.90%-54.98%-58.91%-42.36%-55.64%
Return on Assets (ROA)
-48.45%-40.13%-27.81%-32.67%-24.17%-32.81%
Return on Invested Capital (ROIC)
-53.98%-44.57%-30.28%-36.10%-26.15%-35.16%
Earnings Yield
-41.10%-57.33%-27.05%-158.11%-35.08%-11.70%
FCF Yield
-37.18%-51.68%-26.98%-137.15%-30.08%-7.58%
Buyback Yield / Dilution
-12.57%-21.17%-37.27%-60.30%-113.46%-832.81%
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q